Ultragenyx Pharmaceutical Inc.
RARE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.52B
Close$
$55.30
271.1% upside
Current Fair Value
271.1% upsideUndervalued by 271.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.52 Billion |
|---|---|
| Enterprise Value | $1.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.83 |
| Beta | 0.32 |
| Outstanding Shares | 101,900,000 |
Return
| Return on Equity | 201.52% |
|---|---|
| Return on Assets | -46.39% |
| Return on Invested Capital | -56.67% |
Valuation & Multiples
| P/E Ratio | -2.65 |
|---|---|
| PEG | 13.28 |
| Price to Sales | 2.13 |
| Price to Book Ratio | -4.97 |
| Enterprise Value to Revenue | 2.06 |
| Enterprise Value to EBIT | -2.85 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | -0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-1.22
Average shareholder expectationRevenue Estimate
$183.08 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-1.11
Average shareholder expectationRevenue Estimate
$182.19 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 119.31% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 105.45% |
|---|---|
| Total Invested | $54,800▼ 100.00% |
| Investors Holding | 4▼ 325.00% |
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis